Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1161

Sort by

Sort Order Select

Journal Articles

Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia

Cesar Sommer, PhD, Hsin-Yuan Cheng, PhD, Yik Andy Yeung, PhD, Duy Nguyen, Janette Sutton, Zea Melton, Julien Valton, PhD, Kris Poulsen, Ivana Djuretic, PhD, Thomas Van Blarcom, PhD, Javier Chaparro-Riggers, PhD, Barbra Sasu, PhD

Blood (2019) 134 (Supplement_1): 3921.

https://doi.org/10.1182/blood-2019-129025

Published: 2019

Journal Articles

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Christoph Kornauth, Charles Herbaux, MD MSc, Bernd Boidol, PhD, Chantal Guillemette, Patrick Caron, Stéphanie Poulain, MD PhD, Olivier Tournilhac, Marius E Mayerhoefer, Ulrich Jaeger, MD, Stefan Kubicek, Matthew S. Davids, MD, Philipp Bernhard Staber, MD PhD

Blood (2019) 134 (Supplement_1): 3965.

https://doi.org/10.1182/blood-2019-124392

Published: 2019

Journal Articles

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Sanjal Desai, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Mark A. Ahlman, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 4102.

https://doi.org/10.1182/blood-2019-127481

Published: 2019

Journal Articles

Alemtuzumab as First Line Treatment in Children with Familial Lymphohistiocytosis

Blood (2019) 134 (Supplement_1): 80.

https://doi.org/10.1182/blood-2019-124477

Published: 2019

Journal Articles

Subcutaneous Alemtuzumab Has Activity in Treatment-Naïve Patients with Acquired Aplastic Anemia

Ana Rita Da Fonseca, MD, Anita Hill, MD PhD, Patricia Eiko Yamakawa, MD, Iara Baldim Rabelo, MD PhD, Andre Domingues Pereira, MD, Vinicius Campos de Molla, MD, Matheus Vescovi Gonçalves, MD PhD, Morag Griffin, MD, Talha Munir, MD, Peter Hillmen, MD PhD, Louise Arnold, MD, Kathryn Riley, MD, Antonio M. Risitano, MD PhD, Phillip Scheinberg, MD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2503.

https://doi.org/10.1182/blood-2019-130719

Published: 2019

Journal Articles

First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma

Hongyu Zhang, MD PhD, Jia Feng, MD PhD, Wenli Zhang, MD, Qi Chen, PhD, Yuanzhen Cao, Kevin Pinz, Fang Liu, MD PhD, Yu Ma, Masayuki Wada, PhD, Yupo Ma, MD PhD

Blood (2019) 134 (Supplement_1): 2881.

https://doi.org/10.1182/blood-2019-122789

Published: 2019

Journal Articles

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Satyajit Kosuri, MD, Sang Mee Lee, PhD, Hongtao Liu, MD PhD, Mylove Mortel, MS, RN, Lucy A Godley, MD PhD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Wendy Stock, MD, Justin Kline, MD, Peter A. Riedell, MD, Koen Van Besien, MD PhD, Michael R. Bishop, MD, Andrew S. Artz, MD

Blood (2019) 134 (Supplement_1): 3324.

https://doi.org/10.1182/blood-2019-126211

Published: 2019

Journal Articles

Allogeneic Anti-CD19 CAR T Cells Manufactured from Healthy Donors Provide a Unique Cellular Product with Distinct Phenotypic Characteristics Compared to CAR T Cells Generated from Patients with Mature B Cell Malignancies

Charlotte Graham, MRCP, BSc, MBBS, Agnieszka Jozwik, PhD, Ruby Quartey-Papafio, Nikolaos Ioannou, PhD MSc, BSc, Ana M Metelo, PhD, Carlo Scala, PhD, Glenda Dickson, PhD, Orla Stewart, Maria Almena-Carrasco, Elisa Peranzoni, Alan G. Ramsay, BSc,MSc,PhD, Sandra Dupouy, Pharm.D, PhD, Farzin Farzaneh, PhD, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Andrea Pepper, PhD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD

Blood (2019) 134 (Supplement_1): 3228.

https://doi.org/10.1182/blood-2019-123018

Published: 2019

Journal Articles

Incorporation of Thiotepa in a Reduced Intensity Conditioning Regimen Leads to Improved Engraftment after Stem Cell Transplant for Patients with Hemophagocytic Lymphohistiocytosis

Swati Naik, MBBS, Olive S. Eckstein, MD, Ghadir Sasa, MD, Robert A. Krance, MD, Carl E. Allen, MD PhD, Helen E. Heslop, MD DSc, Caridad A. Martinez, MD

Blood (2019) 134 (Supplement_1): 3273.

https://doi.org/10.1182/blood-2019-132120

Published: 2019

Journal Articles

Role of Disease Mechanism in Hematopoietic Cell Transplantation Outcomes for Hemophagocytic Lymphohistiocytosis

Aleksandra S. Dain, MD, Michelle L. Hermiston, MD PhD, Kristin A. Shimano, MD, Sandhya Kharbanda, MD, Alexis Melton, MD PhD, Jasmeen Dara, MD, James N Huang, MD, Christopher C. Dvorak, MD

Blood (2019) 134 (Supplement_1): 3343.

https://doi.org/10.1182/blood-2019-127397

Published: 2019

Journal Articles

Universal' Fratricide-Resistant CAR T Cells Against T Cell Leukemia Generated By Coupled & Uncoupled Deamination Mediated Base Editing

Christos Georgiadis, PhD, Jane Rasaiyaah, PhD, Soragia Athina Gkazi, PhD, Roland Preece, Annie Etuk, PhD, Abraham Christi, Waseem Qasim, MBBS, PhD

Blood (2019) 134 (Supplement_1): 3219.

https://doi.org/10.1182/blood-2019-130057

Published: 2019

Journal Articles

Results of Unrelated Donor Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Europe on Behalf of Paediatric Diseases (PDWP) and Inborn Errors Working Parties (IEWP) of the EBMT

Blood (2019) 134 (Supplement_1): 4583.

https://doi.org/10.1182/blood-2019-121952

Published: 2019

Journal Articles

Low Numbers of CD27 - IgD - 'Double Negative' Senescent B-Cells Early after Reduced Intensity T Cell Depleted Haematopoietic Stem Cell Transplantation Are Predictive of Subsequent Chronic GvHD

Francesca Kinsella, PhD MRCP, FRCPath, Harriet Protheroe, MBChB BSc, Hayden Pearce, BSc. (Hons.), PhD, Charlotte F Inman, BVSc, PhD, Suzy A Eldershaw, BSc. (Hons.), PhD, Joanne Croudace, PhD, Ben E Abbotts, BSc. (Hons.), MSc., Jianmin Zuo, PhD, Ram K Malladi, FRCPath, Charles Craddock, FRCP, FRCPath, Paul Moss, MBBS, PhD FRCP

Blood (2019) 134 (Supplement_1): 4529.

https://doi.org/10.1182/blood-2019-131130

Published: 2019

Journal Articles

Elimination of Acute GvHD with Three Doses of Abatacept Prophylaxis Combined with Post-Transplant Cyclophosphamide after Myeloablative Treosulfan-Based Conditioning in the HLA Identical Sibling and Unrelated (10-12/12) Peripheral Blood Stem Cell Donor Setting: Improved Safety and Efficacy Compared to Alemtuzumab Prophylaxis

Amit Patel, MBBS,PhDFRCPath,MRCP, Jun Yong, MBChB, MRCP(UK)

Blood (2019) 134 (Supplement_1): 4540.

https://doi.org/10.1182/blood-2019-130184

Published: 2019

Journal Articles

The Proportion of CD52/GPI Negative T Cells Early Following Alemtuzumab Conditioned Haematopoetic Stem Cell Transplantation Is an Independent Risk Factor for Acute GvHD

Francesca Kinsella, PhD MRCP, FRCPath, Charlotte F Inman, BVSc, PhD, Duncan Murray, FRCPath, MRCP, MA, BMBS, Wayne Croft, PhD, Jianmin Zuo, PhD, Hayden Pearce, BSc. (Hons.), PhD, Sara Barbieri, BSc MSc, Jane Nunnick, BSC. (Hons.), MSc., Sandeep Nagra, MBChB, Charles Craddock, FRCP, FRCPath, Ram K Malladi, FRCPath, Paul Moss, MBBS, PhD FRCP

Blood (2019) 134 (Supplement_1): 4543.

https://doi.org/10.1182/blood-2019-128292

Published: 2019

Journal Articles

Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants

Cristina F Contreras, BS, Janel R Long-Boyle, PharmD, PhD, Kristin A. Shimano, MD, Jasmeen Dara, MD, James N Huang, MD, Sandhya Kharbanda, MD, Alexis Melton, MD PhD, Christine Higham, MD, Morton J Cowan, MD, Christopher C. Dvorak, MD

Blood (2019) 134 (Supplement_1): 4481.

https://doi.org/10.1182/blood-2019-127218

Published: 2019

Journal Articles

Investigation of Allocar T TM Targeting CD70 As a Potential Therapy for an Array of Hematological Malignancies

Siler Panowski, PhD, Surabhi Srinivasan, MS, Thomas Van Blarcom, PhD, Cesar Sommer, PhD, Hsin-Yuan Cheng, PhD, Thomas Pertel, PhD, Marianne A Santaguida, PhD, Roman Galetto, PhD, Alan Dunlop, BSc, MSc, Reuben Benjamin, MD, Barbra Sasu, PhD

Blood (2019) 134 (Supplement_1): 5157.

https://doi.org/10.1182/blood-2019-128808

Published: 2019

Journal Articles

Highly Efficient Multiplexed Base Editing with Minimized Off-Targets for the Development of Universal CAR-T Cells to Treat Pediatric T-ALL

Jason M Gehrke, PhD, Aaron Edwards, MS, Ryan C. Murray, MS, Amy Shaw, MS, Yeh-Chuin Poh, PhD, Sarah Smith, Yi Yu, PhD, Nicole M. Gaudelli, PhD, Waseem Qasim, MBBS, PhD, Giuseppe Ciaramella, PhD, B.Sc.

Blood (2019) 134 (Supplement_1): 5127.

https://doi.org/10.1182/blood-2019-130562

Published: 2019

Journal Articles

Differential Alemtuzumab Dosage Effects in T-Cell Deplete Allogeneic Haematopoietic Stem Cell Transplants for Myeloid Malignancies- King's College Hospital London Experience

Varun Mehra, MBBS,MRCP,FRCPath, Daniele Avenoso, MD, Ximena Cabrera Castellano, Adrian Choy, Stefani Widya, Mili Shah, FRCPath, Shafqat Inam, MD, Shreyans Gandhi, MBBS,MDDNB,MRCP,FRCPath,MPhil, Austin Kulasekararaj, MD MRCP, FRCPath, Francesco Dazzi, PhD, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Hugues De Lavallade, Victoria Potter, MBBS, BSc, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4622.

https://doi.org/10.1182/blood-2019-131239

Published: 2019

Journal Articles

Adding Azathioprine and Hydroxyurea Preconditioning to Alemtuzumab/TBI May Improve Donor Chimerism in Matched Sibling Donor Allogeneic Stem Cell Transplantation in Adult Sickle Cell Patients

Erfan Nur, MD PhD, Sacha S Zeerleder, MD PhD, Aafke E. Gaartman, MD, Caroline E Rutten, MD PhD, Charlotte F.J. Van Tuijn, MPH, PhD, Liesbeth E.M. Suijk, Mette D Hazenberg, MD PhD, Bart J. Biemond, MD PhD

Blood (2019) 134 (Supplement_1): 997.

https://doi.org/10.1182/blood-2019-129403

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Alemtuzumab as First Line Treatment in Children with Familial Lymphohistiocytosis

Subcutaneous Alemtuzumab Has Activity in Treatment-Naïve Patients with Acquired Aplastic Anemia

First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Allogeneic Anti-CD19 CAR T Cells Manufactured from Healthy Donors Provide a Unique Cellular Product with Distinct Phenotypic Characteristics Compared to CAR T Cells Generated from Patients with Mature B Cell Malignancies

Incorporation of Thiotepa in a Reduced Intensity Conditioning Regimen Leads to Improved Engraftment after Stem Cell Transplant for Patients with Hemophagocytic Lymphohistiocytosis

Role of Disease Mechanism in Hematopoietic Cell Transplantation Outcomes for Hemophagocytic Lymphohistiocytosis

Universal' Fratricide-Resistant CAR T Cells Against T Cell Leukemia Generated By Coupled & Uncoupled Deamination Mediated Base Editing

Results of Unrelated Donor Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Europe on Behalf of Paediatric Diseases (PDWP) and Inborn Errors Working Parties (IEWP) of the EBMT

Low Numbers of CD27 - IgD - 'Double Negative' Senescent B-Cells Early after Reduced Intensity T Cell Depleted Haematopoietic Stem Cell Transplantation Are Predictive of Subsequent Chronic GvHD

The Proportion of CD52/GPI Negative T Cells Early Following Alemtuzumab Conditioned Haematopoetic Stem Cell Transplantation Is an Independent Risk Factor for Acute GvHD

Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants

Investigation of Allocar T TM Targeting CD70 As a Potential Therapy for an Array of Hematological Malignancies

Highly Efficient Multiplexed Base Editing with Minimized Off-Targets for the Development of Universal CAR-T Cells to Treat Pediatric T-ALL

Differential Alemtuzumab Dosage Effects in T-Cell Deplete Allogeneic Haematopoietic Stem Cell Transplants for Myeloid Malignancies- King's College Hospital London Experience

Adding Azathioprine and Hydroxyurea Preconditioning to Alemtuzumab/TBI May Improve Donor Chimerism in Matched Sibling Donor Allogeneic Stem Cell Transplantation in Adult Sickle Cell Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only